Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. REACH-2 was a randomised, doub...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 20; číslo 2; s. 282 - 296
Hlavní autoři:	Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.02.2019 Elsevier Limited Elsevier
Témata:	Aged Alpha-Fetoproteins / analysis Angiogenesis Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Agents - administration & dosage Aspartate aminotransferase Biomarkers Cancer Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cirrhosis Clinical trials Double-Blind Method Double-blind studies Drug Therapy, Combination Female Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Intravenous administration Life Sciences Liver cancer Liver cirrhosis Liver diseases Liver Neoplasms - blood Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Medical prognosis Middle Aged Monoclonal antibodies Neoplasm Staging Oncology Patients Ramucirumab Renal failure Safety Sorafenib - administration & dosage Studies Survival Targeted cancer therapy Thromboembolism Treatment Outcome
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!